Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Rating Upgraded by Jefferies Financial Group

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) was upgraded by investment analysts at Jefferies Financial Group from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Friday, Marketbeat.com reports. The firm currently has a $21.00 price objective on the biotechnology company’s stock, up from their previous price objective of $10.00. Jefferies Financial Group’s price target would indicate a potential upside of 43.74% from the stock’s previous close.

Several other equities analysts also recently weighed in on AUPH. Royal Bank Of Canada reissued a “sector perform” rating and set a $15.00 price target (up previously from $9.00) on shares of Aurinia Pharmaceuticals in a research report on Wednesday. Weiss Ratings reiterated a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a research report on Wednesday, October 8th. HC Wainwright restated a “buy” rating and issued a $17.00 target price on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 30th. Finally, Bloom Burton cut shares of Aurinia Pharmaceuticals from a “moderate buy” rating to a “hold” rating in a research note on Wednesday. Two investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $17.67.

Aurinia Pharmaceuticals Stock Performance

Shares of AUPH opened at $14.61 on Friday. Aurinia Pharmaceuticals has a 12-month low of $6.55 and a 12-month high of $16.20. The stock has a market cap of $1.92 billion, a P/E ratio of 33.98 and a beta of 1.30. The company has a current ratio of 5.23, a quick ratio of 4.63 and a debt-to-equity ratio of 0.18. The company has a 50-day moving average of $12.28 and a two-hundred day moving average of $10.18.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.23 earnings per share for the quarter, topping analysts’ consensus estimates of $0.16 by $0.07. Aurinia Pharmaceuticals had a net margin of 23.31% and a return on equity of 20.06%. The business had revenue of $73.47 million during the quarter, compared to analysts’ expectations of $67.70 million. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, research analysts predict that Aurinia Pharmaceuticals will post 0.11 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. GAMMA Investing LLC grew its holdings in Aurinia Pharmaceuticals by 56.1% in the first quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company’s stock valued at $39,000 after purchasing an additional 1,744 shares during the period. MAI Capital Management acquired a new position in shares of Aurinia Pharmaceuticals in the 1st quarter valued at $39,000. DekaBank Deutsche Girozentrale acquired a new position in shares of Aurinia Pharmaceuticals in the 1st quarter valued at $60,000. State of Alaska Department of Revenue purchased a new stake in shares of Aurinia Pharmaceuticals during the 3rd quarter valued at $91,000. Finally, USA Financial Formulas acquired a new stake in shares of Aurinia Pharmaceuticals during the 3rd quarter worth $107,000. 36.83% of the stock is currently owned by hedge funds and other institutional investors.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.